DK1079834T3 - Stabile sammensætninger omfattende levosimendan og alginsyre - Google Patents

Stabile sammensætninger omfattende levosimendan og alginsyre

Info

Publication number
DK1079834T3
DK1079834T3 DK99916943T DK99916943T DK1079834T3 DK 1079834 T3 DK1079834 T3 DK 1079834T3 DK 99916943 T DK99916943 T DK 99916943T DK 99916943 T DK99916943 T DK 99916943T DK 1079834 T3 DK1079834 T3 DK 1079834T3
Authority
DK
Denmark
Prior art keywords
levosimendan
alginic acid
stable compositions
compositions
stable
Prior art date
Application number
DK99916943T
Other languages
Danish (da)
English (en)
Inventor
Maarit Baeckmann
Ilkka Larma
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of DK1079834T3 publication Critical patent/DK1079834T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Jellies, Jams, And Syrups (AREA)
  • Detergent Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
DK99916943T 1998-04-23 1999-04-23 Stabile sammensætninger omfattende levosimendan og alginsyre DK1079834T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FI980902A FI980902A7 (fi) 1998-04-23 1998-04-23 Levosimendaanin stabiileja koostumuksia
PCT/FI1999/000331 WO1999055337A1 (en) 1998-04-23 1999-04-23 Stabile compositions comprising levosimendan and alginic acid

Publications (1)

Publication Number Publication Date
DK1079834T3 true DK1079834T3 (da) 2003-04-07

Family

ID=8551576

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99916943T DK1079834T3 (da) 1998-04-23 1999-04-23 Stabile sammensætninger omfattende levosimendan og alginsyre

Country Status (32)

Country Link
US (1) US6531458B1 (cs)
EP (1) EP1079834B1 (cs)
JP (1) JP4475809B2 (cs)
KR (1) KR100590622B1 (cs)
CN (1) CN1165309C (cs)
AT (1) ATE231395T1 (cs)
AU (1) AU756338B2 (cs)
BG (1) BG64766B1 (cs)
BR (1) BR9909867A (cs)
CA (1) CA2329232C (cs)
CZ (1) CZ290911B6 (cs)
DE (1) DE69905034T2 (cs)
DK (1) DK1079834T3 (cs)
EA (1) EA002428B1 (cs)
EE (1) EE04143B1 (cs)
ES (1) ES2191426T3 (cs)
FI (1) FI980902A7 (cs)
GE (1) GEP20032942B (cs)
HR (1) HRP20000703B1 (cs)
HU (1) HUP0105446A3 (cs)
ID (1) ID26650A (cs)
IL (2) IL138950A0 (cs)
MX (1) MXPA00010368A (cs)
NO (1) NO318575B1 (cs)
NZ (1) NZ507455A (cs)
PL (1) PL192274B1 (cs)
PT (1) PT1079834E (cs)
RS (1) RS49955B (cs)
SK (1) SK284600B6 (cs)
TR (1) TR200003101T2 (cs)
WO (1) WO1999055337A1 (cs)
ZA (1) ZA200005630B (cs)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI980901A7 (fi) * 1998-04-23 1999-10-24 Orion Yhtymae Oyj Levosimendaania säädellysti vapauttavia oraalisia koostumuksia
FI109659B (fi) * 1999-09-10 2002-09-30 Orion Yhtymae Oyj Levosimendaanin farmaseuttisia liuoksia
FI20010233A0 (fi) * 2001-02-08 2001-02-08 Orion Corp Menetelmä sydämen vajaatoiminnan hoitoon
WO2002064120A1 (fr) * 2001-02-13 2002-08-22 Taisho Pharmaceutical Co., Ltd. Preparations de gel a usage interne
JP2008533109A (ja) * 2005-03-14 2008-08-21 オリオン コーポレーション 利尿を促進するための複合治療
JP6770754B2 (ja) * 2015-11-06 2020-10-21 カリノファルム・ゲーエムベーハーCarinopharm Gmbh 輸液又は注射として及び輸液濃縮物の静脈内投与のためのレボシメンダンの改善された調製物
JP2023507626A (ja) 2019-12-16 2023-02-24 テナックス・セラピューティクス,インコーポレイテッド 駆出率が保たれた心不全を伴う肺高血圧症(PH-HF-pEF)を治療するためのレボシメンダン

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1509866A (en) 1975-06-10 1978-05-04 Johnson & Johnson Enteric coated digestive enzyme compositions
AU555304B2 (en) * 1982-04-05 1986-09-18 Merck Sharp & Dohme Limited Stabilization of drugs in alginic acid and magnesium hydroxide granules
EP0123291A2 (en) 1983-04-20 1984-10-31 Kyowa Hakko Kogyo Co., Ltd. Method for stabilizing interferon
US4906630A (en) * 1985-11-22 1990-03-06 Rorer Pharmaceutical Corporation Method of increasing cardiac contractility using pharmaceutical compositions comprising benzodiazinone- pyridazinone or hydroxy-pyrazolyl compounds
US4716042A (en) * 1986-06-16 1987-12-29 American Home Products Corporation Stabilized coated aspirin tablets
GB8903130D0 (en) 1989-02-11 1989-03-30 Orion Yhtymae Oy Substituted pyridazinones
GB2251615B (en) * 1991-01-03 1995-02-08 Orion Yhtymae Oy (-)-[[4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl]hydrazono]pro panedinitrile
GB2266841A (en) 1992-05-06 1993-11-17 Orion Yhtymae Oy Compounds for use as anti-ischemic medicaments
GB9614098D0 (en) * 1996-07-05 1996-09-04 Orion Yhtymae Oy Transdermal delivery of levosimendan
FI973804A7 (fi) * 1997-09-26 1999-03-27 Orion Yhtymae Oy Levosimendaanin oraalisia koostumuksia

Also Published As

Publication number Publication date
BG104958A (bg) 2001-07-31
JP2002512964A (ja) 2002-05-08
SK15552000A3 (sk) 2001-05-10
EE04143B1 (et) 2003-10-15
YU64000A (sh) 2002-12-10
DE69905034T2 (de) 2003-09-04
PT1079834E (pt) 2003-04-30
CN1165309C (zh) 2004-09-08
ATE231395T1 (de) 2003-02-15
PL343722A1 (en) 2001-09-10
HUP0105446A2 (hu) 2002-07-29
GEP20032942B (en) 2003-04-25
IL138950A (en) 2006-08-20
HRP20000703B1 (hr) 2009-11-30
IL138950A0 (en) 2001-11-25
EA200001097A1 (ru) 2001-04-23
KR20010072577A (ko) 2001-07-31
EP1079834B1 (en) 2003-01-22
EE200000616A (et) 2002-06-17
ES2191426T3 (es) 2003-09-01
NO20005312L (no) 2000-11-21
EA002428B1 (ru) 2002-04-25
CZ20003779A3 (en) 2001-05-16
JP4475809B2 (ja) 2010-06-09
US6531458B1 (en) 2003-03-11
FI980902A0 (fi) 1998-04-23
DE69905034D1 (de) 2003-02-27
ZA200005630B (en) 2002-01-14
WO1999055337A1 (en) 1999-11-04
CA2329232C (en) 2007-10-30
MXPA00010368A (es) 2002-07-02
NZ507455A (en) 2002-02-01
HRP20000703A2 (en) 2001-04-30
FI980902A7 (fi) 1999-10-24
PL192274B1 (pl) 2006-09-29
SK284600B6 (sk) 2005-07-01
BG64766B1 (bg) 2006-03-31
TR200003101T2 (tr) 2001-01-22
ID26650A (id) 2001-01-25
HUP0105446A3 (en) 2002-09-30
AU756338B2 (en) 2003-01-09
AU3524899A (en) 1999-11-16
CN1298303A (zh) 2001-06-06
EP1079834A1 (en) 2001-03-07
NO20005312D0 (no) 2000-10-20
BR9909867A (pt) 2000-12-19
CA2329232A1 (en) 1999-11-04
RS49955B (sr) 2008-09-29
HK1031998A1 (en) 2001-07-06
NO318575B1 (no) 2005-04-11
CZ290911B6 (cs) 2002-11-13
KR100590622B1 (ko) 2006-06-19

Similar Documents

Publication Publication Date Title
DE60013098D1 (de) Zusammensetzung zur hautdesinfizierung
DE60223262D1 (de) Verwendung von fucanen in der behandlung von adhäsion, arthritis und psoriasis
NO992617L (no) Sulfinsyrederivater, deres fremstilling og anvendelse
ATE289332T1 (de) Silikongel enthaltend salizylsäure
RS49756B (sr) Primena ksenona ili smeša ksenonskog gasa za proizvodnju farmaceutskog preparata za lečenje neurointoksikacija
DE60143906D1 (de) Verwendung von derivaten der 2-oxothiazolidin-4-corbonsäure als prä-abschuppungsmittel
ATE297188T1 (de) Stabilisierte ascorbinsäure-lösungen
NO20061138L (no) Gjaercellevegger for behandling eller forebygging av hyperglukemi eller for a stabilisere glukemi
ATE213937T1 (de) Spezielle halofantrinhaltige zusammensetzungen
DE60130661D1 (de) Verwendung der 13-cis retinsäure zur behandlung von emphysemen
DK1079834T3 (da) Stabile sammensætninger omfattende levosimendan og alginsyre
NO20003758L (no) Trekonserveringsmidler
ATE217191T1 (de) Verwendung von phanquinon zur behandlung von alzheimer's krankheit
DK0921806T3 (da) Mannose-6-phosphat-præparat og anvendelse deraf til behandling af fibrøse lidelser
TR200200278T2 (tr) Kalsilitik bileşimler
DE60219940D1 (de) Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
NO970573D0 (no) Ylidenforbindelser og deres fremstilling
RS95304A (en) New combination fortreating airway disorders
ATE361757T1 (de) Stabile fumagillin-formulierung
ATE302023T1 (de) Verwendung von stickstoffoxid zur behandlung von atemwegs-verengungen
DE60137506D1 (de) Verwendung von polysulfatierten cyclodextrinen zur behandlung von arthrose
DE60012836D1 (de) Verwendung von Simethicone zur Behandlung der ulzerativen Kolitis
ATE184155T1 (de) Verwendung der jodwasserstoffsäure als aphrodisiakum
DE50003481D1 (de) Verwendung von schmutzablösenden formulierungen zur behandlung von oberflächen
DE69626010D1 (de) Verwendung von tropolon derivate zur hemmung des inositmono phosphatase